Oracle’s stock (ORCL) experienced a historic rally today, surging as much as 42% following news of unprecedented demand for its AI-driven cloud infrastructure and record-breaking contract wins. This marks Oracle’s largest single-day gain since the 1990s and sets a record for companies with market…
The InterGroup Corporation (NASDAQ: INTG) is emerging as a compelling turnaround story in 2025, combining solid real estate assets with a strategic push to unlock shareholder value and capitalize on market dislocations.
Recent Highlights and Stock Momentum
In August, InterGroup’s (INTG) shares…
London-listed Anglo American (AAL.L) and Canada's Teck Resources (TECK-B.TO) have sealed a transformative, “merger of equals” deal that will reshape the mining landscape—creating a copper powerhouse with a combined market capitalization north of $53 billion, headquarters in Vancouver, and core operations spanning…
NVIDIA’s (NVDA) meteoric rise from Silicon Valley upstart to AI infrastructure leader is deeply intertwined with the vision and resilience of its founder-CEO, Jensen Huang. An immigrant who experienced hardship and displacement as a youth in Taiwan and the U.S., Huang sharpened…
Gold has achieved a historic milestone in 2025, with central banks now holding more gold in their reserves than U.S. Treasuries for the first time since 1996—a shift signaling profound changes in global finance and monetary management.
Central Banks Shift to Gold…
Eupraxia Pharmaceuticals (NASDAQ: EPRX) is defining a new frontier in the treatment of eosinophilic esophagitis (EoE) with its innovative candidate, EP-104GI. This investigational therapy, developed with Eupraxia’s proprietary DiffuSphere™ technology, delivers long-lasting and locally targeted steroid treatment directly into the esophageal wall—offering…
Eupraxia Pharmaceuticals (NASDAQ: EPRX) has recently achieved several pivotal milestones, signaling increased momentum in its late-stage clinical programs and drawing strong endorsements from Wall Street analysts, while shares of Eupraxia have risen ~100% over the last 12 months. The company’s clinical progress,…
HCW Wainwright has reiterated its Buy rating on Serina Therapeutics (NYSE American: SER), emphasizing both the company’s clinical progress and robust valuation metrics as key drivers for investor optimism.
Company Snapshot and Market Performance
Serina Therapeutics (SER) currently trades at $5.04 per share with a market…
U.S. corporations have crossed an extraordinary threshold in 2025, shattering records by eclipsing $1 trillion in share buybacks before the close of August—faster than any year in history. This landmark moment underscores a potent undercurrent of confidence among America’s corporate titans, driven…
MongoDB, Inc. (MDB) is riding a wave of momentum, decisively positioning itself as a foundational enabler of the artificial intelligence revolution with robust financials, rapid customer growth, and strategic innovation initiatives. Over the past several months, a steady cadence of announcements—ranging from…
